The FASEB Journal, Vol 9, 190-199, Copyright © 1995 by The Federation of American Societies for Experimental Biology

REVIEWS

Targeted vectors for gene therapy

N Miller and R Vile
Laboratory of Cancer Gene Therapy, Rayne Institute, St. Thomas' Hospital, London, United Kingdom.

Successful gene therapy requires not only the identification of an appropriate therapeutic gene for treatment of the disease, but also a delivery system by which that gene can be delivered to the desired cell type both efficiently and accurately. Reductions in accuracy will inevitably also reduce efficiency since fewer particles will be available for delivery to the correct cells if many are sequestered into nontarget cells. In addition, the therapy will have net benefit to the patient only if gene delivery is sufficiently restricted such that normal cells are left unaffected by any detrimental affects of bystander cell transduction. Here we review how currently available delivery systems, both plasmid and viral, can be manipulated to improve their targeting to specific cell types. Currently, targeting is achieved by engineering of the surface components of viruses and liposomes to achieve discrimination at the level of target cell recognition and/or by incorporating transcriptional elements into plasmid or viral genomes such that the therapeutic gene is expressed only in certain target cell types. In addition, we discuss emerging vectors and suggest how gene therapy delivery systems of the future will be composites of the best features of diverse vectors already in use.

This article has been cited by other articles:

				S. E. Campbell, D. Bennett, L. Nasir, E. A. Gault, and D. J. Argyle Disease- and cell-type-specific transcriptional targeting of vectors for osteoarthritis gene therapy: further development of a clinical canine model Rheumatology, June 1, 2005; 44(6): 735 - 743. [Abstract] [Full Text] [PDF]

				D. P. McIntosh, X.-Y. Tan, P. Oh, and J. E. Schnitzer Targeting endothelium and its dynamic caveolae for tissue-specific transcytosis in vivo: A pathway to overcome cell barriers to drug and gene delivery PNAS, February 19, 2002; 99(4): 1996 - 2001. [Abstract] [Full Text] [PDF]

				K M Kurian, C J Watson, and A H Wyllie Retroviral vectors Mol. Pathol., August 1, 2000; 53(4): 173 - 176. [Abstract] [Full Text]

				H. Youssoufian, F. A.E. Kruyt, and X. Li Protein Replacement by Receptor-Mediated Endocytosis Corrects the Sensitivity of Fanconi Anemia Group C Cells to Mitomycin C Blood, January 1, 1999; 93(1): 363 - 369. [Abstract] [Full Text] [PDF]

				R. M. Diaz, T. Eisen, I. R. Hart, and R. G. Vile Exchange of Viral Promoter/Enhancer Elements with Heterologous Regulatory Sequences Generates Targeted Hybrid Long Terminal Repeat Vectors for Gene Therapy of Melanoma J. Virol., January 1, 1998; 72(1): 789 - 795. [Abstract] [Full Text] [PDF]

				P. S. Goedegebuure and T. J. Eberlein Vaccine Trials for the Clinician: Prospects for Viral and Non-Viral Vectors Oncologist, October 1, 1997; 2(5): 300 - 310. [Abstract] [Full Text] [PDF]

				H. Prentice, N. H Bishopric, M. N Hicks, D. J Discher, X. Wu, A. A Wylie, and K. A Webster Regulated expression of a foreign gene targeted to the ischaemic myocardium Cardiovasc Res, September 1, 1997; 35(3): 567 - 574. [Abstract] [Full Text] [PDF]